Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry.

ABSTRACT:

Background

Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans ('triptan resistance') could be considered eligible for treatment with the novel medications from the ditan and gepant groups. There is little data on the frequency of 'triptan resistance'.

Methods

We used patient self-report data from the German Migraine and Headache Society (DMKG) Headache Registry to assess triptan response and triptan efficacy and/or tolerability failure.

Results

A total of 2284 adult migraine patients (females: 85.4%, age: 39.4 ± 12.8 years) were included. 42.5% (n = 970) had failed ≥ 1 triptan, 13.1%

SUBMITTER: Ruscheweyh R 

PROVIDER: S-EPMC10563311 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature